Key facts
- This page summarizes Stephen C. Mccluski's Form 4 filing for ImmunoGen, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Sep 2023, 17:30.
Stephen C. Mccluski - 13 Sep 2023 Form 4 Insider Report for ImmunoGen, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 13 Sep 2023
- Net transaction value
- -$13,500
- SEC form
- 4
- Accepted by SEC
- 14 Sep 2023, 17:30:38 UTC
- Prior SEC filing
- 17 Aug 2023
- Next SEC filing
- 12 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen C. Mccluski filed Form 4 for ImmunoGen, Inc. on 14 Sep 2023.
Change
- Previous filing in this sequence was filed on 17 Aug 2023.
- Current net transaction value: -$13,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMGN
transaction
Common Stock
Options Exercise
- Transaction value
- $147,000
- Shares
- +10,000
- Change %
- Price
- $14.70
- Shares after
- 10,000
- Date
- 13 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
IMGN
transaction
Common Stock
Options Exercise
- Transaction value
- $160,500
- Shares
- -10,000
- Change %
- -100%
- Price
- $16.05
- Shares after
- 0
- Date
- 13 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGN
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 13 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $14.70
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Effected pursuant to a trading plan adopted on June 14, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
Footnote F3
This option was granted on 11/12/2013 and is fully vested as of the transaction date.